ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors

• US 7,897,623 B2
• Filed: 08/27/2007
• Issued: 03/01/2011
• Est. Priority Date: 01/13/1999
• Status: Expired due to Fees

• Current Assignee: Bayer Healthcare LLC (Bayer AG)
• Original Assignee: Bayer Healthcare LLC (Bayer AG)
• Inventors: Monahan, Mary-Katherine, Lowinger, Timothy B., Dumas, Jacques, Natero, Reina, Smith, Roger A., Renick, Joel, Khire, Uday R., Wood, Jill E., Sibley, Robert N., Riedl, Bernd, Scott, William J.
• Primary Examiner(s): Henley, III; Raymond J
• Application Number:
  US11/845,597
• Publication Number:
  US 20080027061A1
• Time in Patent Office: 1,282 Days
• Field of Search: 514/346
• US Class Current: 514/346
• CPC Class Codes: A61K 31/17 having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64
• CPC Class Codes: A61K 31/18 Sulfonamides compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63
• CPC Class Codes: A61K 31/24 having an amino or nitro group
• CPC Class Codes: A61K 31/341 not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61K 31/4035 Isoindoles, e.g. phthalimide
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/4439 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole nicotine A61K31/465
• CPC Class Codes: A61K 31/4453 only substituted in position 1, e.g. propipocaine, diperodon
• CPC Class Codes: A61K 31/495 having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazinesA61K31/48 takes precedence ; with three nitrogen atoms A61K31/53
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 31/535 having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
• CPC Class Codes: A61K 31/5375 1,4-Oxazines, e.g. morpholine
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.

Claims

1. A pharmaceutical composition comprising N-(4-chloro-3-(trifluoromethyl)phenyl)-N′

-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea of the formula X

2. The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable salt thereof is a tosylate salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N′

-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea of the formula X

3. A pharmaceutical composition comprising N-(4-chloro-3-(trifluoromethyl)phenyl)-N′

-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea of the formula X

4. The pharmaceutical composition of claim 3 wherein the pharmaceutically acceptable salt thereof is a tosylate salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N′

-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea of the formula X

5. A tablet comprising N-(4-chloro-3-(trifluoromethyl)phenyl)-N′

-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea of the formula X

6. A tablet of claim 5 wherein the pharmaceutically acceptable salt thereof is a tosylate salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N′

-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea of the formula X

7. A tablet of claim 5 wherein the pharmaceutically acceptable excipient is a diluent, a granulating agent, a disintegrating agent or a binding agent.

8. A tablet of claim 6 wherein the pharmaceutically acceptable excipient is a diluent, a granulating agent, a disintegrating agent or a binding agent.